Technology - ACCURATE | Technology Platform of Organoid in Scientific Research, Drug Development and Precision Medicine

ACCURATE

Technology Platform of Organoid in Scientific Research, Drug Development and Precision Medicine

Leading by the world's top scientists from Clinical Medicine, Medical Biology, Pharmaceutical Biology and Molecular Medicine research areas, ACCURATE has established six core technical platforms, which include Accuroid® Organoid Modelling Platform, AI Organoid Quality Control Platform, ADST Automated and High-throughput Drug Sensitivity Testing Platform, Accurate Organoid Data Analysis Platform, Clinical Service Platform as well as New Drug R&D Platform.

Technology Platform of Organoid

Accuroid® Organoid Modelling Platform

AI Organoid Quality Control Platform

ADST Automated and High-throughput Drug Sensitivity Testing Platform

Accurate Organoid Data Analysis Platform

Clinical Service Platform

New Drug R&D Platform

Publications

In collaboration with a number of national medical centers and top research institutions, ACCURATE has published 19 clinical- or/and basic research works. These studies include tumor organoid model generation and clinical predictor capability examination of diverse cancer types, as well as establishment of other disease models and tissue repair capability examination of organoid.

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Cell Reports Medicine 2023

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Anti-colon cancer effects of Spirulina polysaccharide and its mechanism based on 3D models

International Journal of Biological Macromolecules 2023

Anti-colon cancer effects of Spirulina polysaccharide and its mechanism based on 3D models

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/MET amp untreated patients with advanced non-small cell lung cancer

Thoracic Cancer 2022

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/MET amp untreated patients with advanced non-small cell lung cancer

Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma

Annals of Translational Medicine 2022

Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma

Patents

ACCURATE possess a comprehensive system of independent intellectual properties for its applications among individualized cancer therapy, new drug development and regenerative medicine.

Small Intestine Organoid

Organoid

is an in vitro self-organized three-dimensional tissue culture that could derived from adult stem cells, embryonic stem cells or inducible pluripotent stem cells. It composes multiple types of cells and demonstrates highly similarity of the genetic background and histological characteristics of indicated tissue due to its self-renewal and differentiation capacities.

Colorectal Cancer Organoid

Tumor Organoid

are organoids derived from tumor surgical resection samples, endoscopic biopsy samples, as well as tumor cells extracted from malignant effusion. The patient-derived tumor organoids (PDTOs) recapitulate histopathological characteristics and genetic features of parental tumors, and are capable for long-term culture, passage, cryopreservation and resuscitation.

Message Board

Please select the type of service

attachment（Each file size limit is 20MB，file format jpg,png,gif,jpeg,bmp,pdf,mp3,mp4,doc,docx,csv,xls,xlsx,ppt,pptx,zip,7z,rar,tar）

Click or drag file to upload

Get code 60s